Predominance of SHV-5 β-lactamase in enteric bacteria causing community-acquired urinary tract infections in Bosnia and Herzegovina

Clinical Microbiology and Infection

Volumn 13, Issue 8, 2007, Pages 820-823

  Uzunovic kamberovic, S ^a   Bedenic, B ^b   Vranes, J ^b  

^a Laboratory for Clinical and Sanitary Microbiology Zenica   (Bosnia and Herzegovina)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Ceftazidime; Escherichia coli; Extended spectrum lactamases; Klebsiella pneumoniae; Resistance; SHV 5

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAMASE; BETA LACTAMASE SHV 5; BETA LACTAMASE TEM 1; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CLAVULANIC ACID; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; RIFAMPICIN; TETRACYCLINE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CONJUGATION; BACTERIUM ISOLATE; BOSNIA AND HERZEGOVINA; CHILD; CLINICAL ARTICLE; COMMUNICABLE DISEASE; CONTROLLED STUDY; ENTEROBACTERIACEAE; ENZYME ANALYSIS; ENZYME SUBSTRATE; ENZYME SYNTHESIS; ESCHERICHIA COLI; FEMALE; GENE TRANSFER; HUMAN; INFANT; ISOELECTRIC FOCUSING; KLEBSIELLA PNEUMONIAE; MALE; NONHUMAN; OUTPATIENT; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SEQUENCE ANALYSIS; URINALYSIS; URINARY TRACT INFECTION;

ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE;

EID: 34447251270     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01747.x     Document Type: Article

References (20)

1. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-951.
2. Uzunovic-Kamberovic S. Antibiotic resistance of coliform organisms from community-acquired urinary tract infections in Zenica-Doboj Canton, Bosnia and Herzegovina. J Antimicrob Chemother 2006; 58: 344-348.
3. Uzunovic-Kamberovic S, Saric D, Sestic S. Community-acquired urinary tract infections by extended-spectrum beta-lactamase-producing Enterobacteriaceae in Zenica-Doboj Canton, Bosnia and Herzegovina. Med Glas 2006; 3: 46-52.
4. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing,12th informational supplement, document M100-S12. Wayne, PA: NCCLS, 2002.
5. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: Hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-878.
6. Elwell LP, Falkow S. The characterization of R plasmids and the detection of plasmid-specified genes. In: Lorian V, ed., Antibiotics in laboratory medicine, 2nd edn. Baltimore: Williams & Wilkins, 1986; 683-721.
7. Matthew MA, Harris AM, Marshall MJ, Ross GW. The use of isoelectric focusing for detection and identification of β-lactamases. J Gen Microbiol 1975; 88: 169-178.
8. Nüesch-Inderbinen MT, Hächler H, Kayser FH. Detection of genes coding for extended-spectrum SHV β-lactamases in clinical isolates by a molecular genetic method, and comparison with the E test. Eur J Clin Microbiol Infect Dis 1996; 15: 398-402.
9. Birnboim HC, Doly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res 1979; 7: 1513-1523.
10. Kaufman ME. Pulsed-field gel electrophoresis. In: Woodford N, Johnsons A, eds, Molecular bacteriology. Protocols and clinical applications. New York: Humana Press, 1998; 33-51.
11. Arpin C, Dubois V, Coulange L. Extended-spectrum β-lactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother 2003; 47: 3506-3514.
12. Sorlózano A, Gutiérrez J, Palanca M, Soto MJ, Piédrola G. High incidence of extended-spectrum β-lactamases among outpatient clinical isolates of Escherichia coli: A phenotypic assessment of NCCLS guidelines and a commercial method. Diagn Microbiol Infect Dis 2004; 50: 131-134.
13. Hryniewicz K, Szczypa K, Sulikowska A, Jankowski K, Betlejewska K, Hryniewicz W. Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J Antimicrob Chemother 2001; 47: 773-780.
14. Rodríguez-Bańo J, Navarro MD, Romero L et.al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-1094.
15. Calbo E, Romani V, Xercavins M et.al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006; 57: 780-783.
16. Valverde A, Coque TM, Sánchez-Moreno MP, Rollan A, Baquero F, Canton R. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004; 42: 4769-4775.
17. Arpin C, Dubois V, Maugein J et.al. Clinical and molecular analysis of extended-spectrum β-lactamase-producing enterobacteria in the community setting. J Clin Microbiol 2005; 43: 5048-5054.
18. Brinas L, Morreno MA, Teshager T, Porrero YSC, Domiguez L, Torres C. Monitoring and characterization of extended-spectrum β-lactamases in Escherichia coli strains from healthy and sick animals in Spain in 2003. Antimicrob Agents Chemother 2005; 49: 1262-1264.
19. Pournaras S, Ikonomidis A, Sofianou D, Tsakris A, Maniatis AN. CTX-M-type β-lactamases affect community Escherichia coli treatment, Greece. Emerg Infect Dis 2004; 10: 1163-1164.
20. Bedenić B, Randegger C, Stobberingh E, Haechler H. Molecular epidemiology of extended-spectrum β-lactamases from Klebsiella pneumoniae strains, isolated in Zagreb, Croatia. Eur J Clin Microbiol Infect Dis 2001; 20: 505-508.